Kidney International Reports最新文献

{"title":"Anticoagulation for the Prevention of Thrombotic Events in Nephrotic Syndrome","authors":"David Massicotte Azarniouch , Daniel J. Crona , Priscilla Karnabi , Bhadran Bose , Patrick H. Nachman , Marc Carrier , Mark Canney , David W. Johnson , Taewoo Lee , Raja Ramachandran , Vivekanand Jha , Nigel S. Key , Vimal K. Derebail","doi":"10.1016/j.ekir.2024.07.013","DOIUrl":"10.1016/j.ekir.2024.07.013","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141851625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Droxidopa for Management of Chronic Hypotension in Hemodialysis","authors":"Anuradha Jayanti , Mohamed Elewa","doi":"10.1016/j.ekir.2024.07.016","DOIUrl":"10.1016/j.ekir.2024.07.016","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141853073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Imlifidase in Highly Sensitized Kidney Transplant Recipients With a Positive Crossmatch Against a Deceased Donor","authors":"Nassim Kamar ,&nbsp;Dominique Bertrand ,&nbsp;Sophie Caillard ,&nbsp;Danièle Pievani ,&nbsp;Marie Joelle Apithy ,&nbsp;Nicolas Congy-Jolivet ,&nbsp;Bertrand Chauveau ,&nbsp;Fabienne Farce ,&nbsp;Arnaud François ,&nbsp;Audrey Delas ,&nbsp;Jérôme Olagne ,&nbsp;Cédric Usureau ,&nbsp;Jean-Luc Taupin ,&nbsp;Gwenda Line Guidicelli ,&nbsp;Lionel Couzi","doi":"10.1016/j.ekir.2024.07.024","DOIUrl":"10.1016/j.ekir.2024.07.024","url":null,"abstract":"<div><h3>Introduction</h3><div>Imlifidase is authorized for desensitization of highly sensitized adult kidney transplant candidates with a positive crossmatch (XM) against a deceased donor. Here, we report on the results for the first 9 patients transplanted in this context who had at least 3 months of follow-up.</div></div><div><h3>Methods</h3><div>The eligibility criteria were as follows: calculated panel reactive antibodies (cPRA) ³ 98%, ³ 3 years on the waiting list, immunodominant donor-specific antibodies (DSAs) with mean fluorescence intensity (MFI) &gt; 6000 (and &lt; 5000 at 1:10 dilution) and a negative post-imlifidase complement-dependent cytotoxic XM (CDCXM).</div></div><div><h3>Results</h3><div>All 9 patients had been on dialysis for an average of 123 ± 41 months, with cPRA at 99% (<em>n</em> = 2) or 100% (<em>n</em> = 7). At transplantation, the mean number of DSAs was 4.3 ± 1.4. The median immunodominant DSA MFI was 9153 (6430–16,980). Flow cytometry XM (FCXM) and CDCXM before imlifidase were positive in 9 and 2 patients, respectively. After 1 injection of imlifidase, all were negative. Patients received polyclonal antibodies, i.v. Igs (IVIg), rituximab, tacrolimus, and mycophenolate. Five patients had a DSA rebound within the first 14 days: 2 had concomitant clinical antibody-mediated rejection (ABMR), 2 had subclinical ABMR, and 1 had isolated positive C4d staining. No ABMR was observed in patients without rebound. Chronic Kidney Disease-Epidemiology Collaboration formula estimated glomerular filtration rate (eGFR) was 56 ± 22 ml/min per 1.73 m² at the last follow-up (7 ± 2.8 months). No graft loss or death were observed. Four patients developed at least 1 infection.</div></div><div><h3>Conclusion</h3><div>These real-life data demonstrate that the use of imlifidase to desensitize highly sensitized patients can have an acceptable short-term efficacy and safety profile in selected patients.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141941312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to Comment on “Effect of Belimumab on Preventing De Novo Renal Lupus Flares”","authors":"Ioannis Parodis ,&nbsp;Alvaro Gomez ,&nbsp;Julius Lindblom ,&nbsp;Brad H. Rovin","doi":"10.1016/j.ekir.2024.07.037","DOIUrl":"10.1016/j.ekir.2024.07.037","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142181700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Q Fever-Related Glomerulonephritis Unveiled by Metagenomic Next-Generation Sequencing","authors":"Yang Li ,&nbsp;Yueping Shen ,&nbsp;Hongyu Yang ,&nbsp;Min Li ,&nbsp;Lei Jiang ,&nbsp;Wei Ma ,&nbsp;Fude Zhou ,&nbsp;Tao Su","doi":"10.1016/j.ekir.2024.07.036","DOIUrl":"10.1016/j.ekir.2024.07.036","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142181701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on “Belimumab on Preventing De Novo Renal Flares”","authors":"Gabriel Figueroa-Parra ,&nbsp;María C. Cuéllar-Gutiérrez ,&nbsp;Alí Duarte-García","doi":"10.1016/j.ekir.2024.04.073","DOIUrl":"10.1016/j.ekir.2024.04.073","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142181703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Losing Much More Than a Transplant: A Qualitative Study of Kidney Transplant Recipients’ Experiences of Graft Failure","authors":"Anita Marie Slominska ,&nbsp;Elizabeth Anne Kinsella ,&nbsp;Saly El-Wazze ,&nbsp;Kathleen Gaudio ,&nbsp;M. Khaled Shamseddin ,&nbsp;Ann Bugeja ,&nbsp;Marie-Chantal Fortin ,&nbsp;Mireille Farkouh ,&nbsp;Amanda Vinson ,&nbsp;Julie Ho ,&nbsp;Shaifali Sandal","doi":"10.1016/j.ekir.2024.07.011","DOIUrl":"10.1016/j.ekir.2024.07.011","url":null,"abstract":"<div><h3>Introduction</h3><div>Kidney transplant recipients with graft failure are a growing cohort of patients who experience high morbidity and mortality. Limited evidence guides their care delivery and patient perspective to improve care processes is lacking. We conducted an in-depth exploration of how individuals experience graft failure, and the specific research question was: “What impact does the loss of an allograft have on their lives?”</div></div><div><h3>Methods</h3><div>We adopted an interpretive descriptive methodological design. Semistructured in-depth narrative interviews were conducted with adult recipients who had a history of ≥1 graft failure. Data were collected until data saturation was achieved and analyzed using an inductive and thematic approach.</div></div><div><h3>Results</h3><div>Our study included 23 participants from 6 provinces of Canada. The majority were on dialysis and not waitlisted for retransplantation (60.9%). Our thematic analysis identified that the lives of participants were impacted by a range of tangible and experiential losses that go beyond the loss of the transplant itself. The themes identified include loss of control, loss of coherence, loss of certainty, loss of hope, loss of quality of life, and loss of the transplant team. Although many perceived that graft failure was inevitable, the majority were unprepared. The confusion about eligibility for retransplantation appears to contribute to these experiences.</div></div><div><h3>Conclusion</h3><div>Individuals with graft failure experience complex mental and emotional challenges which may contribute to poor outcomes. The number of patients with graft failure globally is increasing and our findings can help guide practices aimed at supporting and guiding them toward self-management and adaptive coping.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141849388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"N-acetylcysteine in Kidney Disease: Molecular Mechanisms, Pharmacokinetics, and Clinical Effectiveness","authors":"Estefani Y. Hernández-Cruz ,&nbsp;Omar E. Aparicio-Trejo ,&nbsp;Fadi A. Hammami ,&nbsp;Daniel Bar-Shalom ,&nbsp;Martin Tepel ,&nbsp;Jose Pedraza-Chaverri ,&nbsp;Alexandra Scholze","doi":"10.1016/j.ekir.2024.07.020","DOIUrl":"10.1016/j.ekir.2024.07.020","url":null,"abstract":"<div><div>N-acetylcysteine (NAC) has shown beneficial effects in both acute kidney disease and chronic kidney disease (CKD) in preclinical and clinical studies. Different dosage and administration forms of NAC have specific pharmacokinetic properties that determine the temporal pattern of plasma concentrations of NAC and its active metabolites. Especially in acute situations with short-term NAC administration, appropriate NAC and glutathione (GSH) plasma concentrations should be timely ensured. For oral dosage forms, bioavailability needs to be established for the respective NAC formulation. Kidney function influences NAC pharmacokinetics, including a reduction of NAC clearance in advanced CKD. In addition, mechanisms of action underlying beneficial NAC effects depend on kidney function as well as comorbidities, both involving GSH deficiency, alterations in nuclear factor erythroid 2-related factor 2 (Nrf2)-dependent signaling, oxidative stress, mitochondrial dysfunction, and disturbed mitochondrial bioenergetics. This also applies to nonrenal NAC mechanisms. The timing of preventive NAC administration in relation to potential injury is important. NAC administration seems most effective either preceding, or preceding and paralleling conditions that induce tissue damage. Furthermore, studies suggest that very high concentrations of NAC should be avoided because they could exert reductive stress. Delayed administration of NAC might interfere with endogenous repair mechanisms. In conclusion, studies on NAC treatment regimens need to account for both NAC pharmacokinetics and NAC molecular effects. Kidney function of the patient population and pathomechanisms of the kidney disease should guide rational NAC trial design. A targeted trial approach and biomarker-guided protocols could pave the way for the use of NAC in precision medicine.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141844335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rethinking Living Donor Kidney Transplantation Through a Healthcare System Lens","authors":"Itunu Owoyemi ,&nbsp;Emilio D. Poggio ,&nbsp;Anne M. Huml","doi":"10.1016/j.ekir.2024.08.024","DOIUrl":"10.1016/j.ekir.2024.08.024","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142181663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Missing in Plain Sight No More? Copy Number Variation in Monogenic Kidney Disease","authors":"Julia Jefferis ,&nbsp;Andrew J. Mallett","doi":"10.1016/j.ekir.2024.08.017","DOIUrl":"10.1016/j.ekir.2024.08.017","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142181667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}